Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy

Vaios Karanikas, Stefanos Tsochas, Konstantinos Boukas, Theodora Kerenidi, Marianna Nakou, Jubrail Dahabreh, Theodoros Poularakis, Konstantinos I. Gourgoulianis, Anastasios E. Germenis

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Polyvalent vaccination represents a recent attempt to improve the effectiveness of lung cancer immunotherapy. This study aimed to investigate whether a gene expression pattern of tumor-associated antigens (TAA) would exist indicating that their use will be most appropriate for the polyvalent vaccination of Caucasian non-small cell lung carcinoma (NSCLC) patients. We examined the concomitant expression of genes belonging to different TAA families for which expression frequencies either have never been detected in NSCLC or vary widely in the literature. Results: 15/23 (65%) and 8/23 (35%) tumor samples were found expressing 6-11 and 2-5 out of the 12 examined TAAs, respectively, at levels >1% of the testis reference sample. The most prevalent TAA patterns observed were those of survivin standard (survivin-std)/survivin-2B expressed by 22/23 (95.5%) tumor samples and of survivin-std/survivin-2B/hTERT expressed by 19/23 (82.5%) tumor samples. The expression levels of the survivin-std gene strongly positively correlated to those of the survivin-2B (p = 0.001) and the hTERT genes (p = 0.031). The number of concomitantly expressed genes was found to be positively correlated to the age of the patients (p = 0.001) and the tumor size (p = 0.048). Methods: Tumor material from 23 patients with NSCLC (12 adenocarcinomas, 8 squamous cell carcinomas, 3 bronchiolo - carcinomas) was examined. mRNA transcripts were detected for 5 genes of the survivin family, 5 MAGE-A genes as well as the genes of human telomerase reverse transcriptase (hTERT) and p53, by the use of quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) or semi-quantitative RT-PCR. Conclusion: This study provides evidence that, in Caucasian patients with NSCLC, highly prevalent expression patterns of TAA genes, predominantly of overexpressed TAAs, do exist. This result implies that the combined use of these TAA could help in designing more effective NSCLC immunotherapeutic protocols.

Original languageEnglish
Pages (from-to)345-352
Number of pages8
JournalCancer Biology and Therapy
Volume7
Issue number3
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Neoplasm Antigens
Non-Small Cell Lung Carcinoma
Immunotherapy
Genes
Neoplasms
Reverse Transcription
Vaccination
vif Genes
Gene Expression
Polymerase Chain Reaction
Testis
Squamous Cell Carcinoma
Lung Neoplasms
Adenocarcinoma
Carcinoma
Messenger RNA
human TERT protein

Keywords

  • Human telomerase reverse transcriptase
  • Immunotherapy
  • Lung adenocarcinoma
  • Melanoma-associated antigen
  • p53
  • Quantitative real-time PCR
  • Squamous cell carcinoma
  • Survivin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Karanikas, V., Tsochas, S., Boukas, K., Kerenidi, T., Nakou, M., Dahabreh, J., ... Germenis, A. E. (2008). Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy. Cancer Biology and Therapy, 7(3), 345-352.

Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas : Implications for immunotherapy. / Karanikas, Vaios; Tsochas, Stefanos; Boukas, Konstantinos; Kerenidi, Theodora; Nakou, Marianna; Dahabreh, Jubrail; Poularakis, Theodoros; Gourgoulianis, Konstantinos I.; Germenis, Anastasios E.

In: Cancer Biology and Therapy, Vol. 7, No. 3, 01.03.2008, p. 345-352.

Research output: Contribution to journalArticle

Karanikas, V, Tsochas, S, Boukas, K, Kerenidi, T, Nakou, M, Dahabreh, J, Poularakis, T, Gourgoulianis, KI & Germenis, AE 2008, 'Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy', Cancer Biology and Therapy, vol. 7, no. 3, pp. 345-352.
Karanikas V, Tsochas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J et al. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy. Cancer Biology and Therapy. 2008 Mar 1;7(3):345-352.
Karanikas, Vaios ; Tsochas, Stefanos ; Boukas, Konstantinos ; Kerenidi, Theodora ; Nakou, Marianna ; Dahabreh, Jubrail ; Poularakis, Theodoros ; Gourgoulianis, Konstantinos I. ; Germenis, Anastasios E. / Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas : Implications for immunotherapy. In: Cancer Biology and Therapy. 2008 ; Vol. 7, No. 3. pp. 345-352.
@article{9d9dbbf426984e9c884a1c83cd3aa356,
title = "Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy",
abstract = "Background: Polyvalent vaccination represents a recent attempt to improve the effectiveness of lung cancer immunotherapy. This study aimed to investigate whether a gene expression pattern of tumor-associated antigens (TAA) would exist indicating that their use will be most appropriate for the polyvalent vaccination of Caucasian non-small cell lung carcinoma (NSCLC) patients. We examined the concomitant expression of genes belonging to different TAA families for which expression frequencies either have never been detected in NSCLC or vary widely in the literature. Results: 15/23 (65{\%}) and 8/23 (35{\%}) tumor samples were found expressing 6-11 and 2-5 out of the 12 examined TAAs, respectively, at levels >1{\%} of the testis reference sample. The most prevalent TAA patterns observed were those of survivin standard (survivin-std)/survivin-2B expressed by 22/23 (95.5{\%}) tumor samples and of survivin-std/survivin-2B/hTERT expressed by 19/23 (82.5{\%}) tumor samples. The expression levels of the survivin-std gene strongly positively correlated to those of the survivin-2B (p = 0.001) and the hTERT genes (p = 0.031). The number of concomitantly expressed genes was found to be positively correlated to the age of the patients (p = 0.001) and the tumor size (p = 0.048). Methods: Tumor material from 23 patients with NSCLC (12 adenocarcinomas, 8 squamous cell carcinomas, 3 bronchiolo - carcinomas) was examined. mRNA transcripts were detected for 5 genes of the survivin family, 5 MAGE-A genes as well as the genes of human telomerase reverse transcriptase (hTERT) and p53, by the use of quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) or semi-quantitative RT-PCR. Conclusion: This study provides evidence that, in Caucasian patients with NSCLC, highly prevalent expression patterns of TAA genes, predominantly of overexpressed TAAs, do exist. This result implies that the combined use of these TAA could help in designing more effective NSCLC immunotherapeutic protocols.",
keywords = "Human telomerase reverse transcriptase, Immunotherapy, Lung adenocarcinoma, Melanoma-associated antigen, p53, Quantitative real-time PCR, Squamous cell carcinoma, Survivin",
author = "Vaios Karanikas and Stefanos Tsochas and Konstantinos Boukas and Theodora Kerenidi and Marianna Nakou and Jubrail Dahabreh and Theodoros Poularakis and Gourgoulianis, {Konstantinos I.} and Germenis, {Anastasios E.}",
year = "2008",
month = "3",
day = "1",
language = "English",
volume = "7",
pages = "345--352",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas

T2 - Implications for immunotherapy

AU - Karanikas, Vaios

AU - Tsochas, Stefanos

AU - Boukas, Konstantinos

AU - Kerenidi, Theodora

AU - Nakou, Marianna

AU - Dahabreh, Jubrail

AU - Poularakis, Theodoros

AU - Gourgoulianis, Konstantinos I.

AU - Germenis, Anastasios E.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: Polyvalent vaccination represents a recent attempt to improve the effectiveness of lung cancer immunotherapy. This study aimed to investigate whether a gene expression pattern of tumor-associated antigens (TAA) would exist indicating that their use will be most appropriate for the polyvalent vaccination of Caucasian non-small cell lung carcinoma (NSCLC) patients. We examined the concomitant expression of genes belonging to different TAA families for which expression frequencies either have never been detected in NSCLC or vary widely in the literature. Results: 15/23 (65%) and 8/23 (35%) tumor samples were found expressing 6-11 and 2-5 out of the 12 examined TAAs, respectively, at levels >1% of the testis reference sample. The most prevalent TAA patterns observed were those of survivin standard (survivin-std)/survivin-2B expressed by 22/23 (95.5%) tumor samples and of survivin-std/survivin-2B/hTERT expressed by 19/23 (82.5%) tumor samples. The expression levels of the survivin-std gene strongly positively correlated to those of the survivin-2B (p = 0.001) and the hTERT genes (p = 0.031). The number of concomitantly expressed genes was found to be positively correlated to the age of the patients (p = 0.001) and the tumor size (p = 0.048). Methods: Tumor material from 23 patients with NSCLC (12 adenocarcinomas, 8 squamous cell carcinomas, 3 bronchiolo - carcinomas) was examined. mRNA transcripts were detected for 5 genes of the survivin family, 5 MAGE-A genes as well as the genes of human telomerase reverse transcriptase (hTERT) and p53, by the use of quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) or semi-quantitative RT-PCR. Conclusion: This study provides evidence that, in Caucasian patients with NSCLC, highly prevalent expression patterns of TAA genes, predominantly of overexpressed TAAs, do exist. This result implies that the combined use of these TAA could help in designing more effective NSCLC immunotherapeutic protocols.

AB - Background: Polyvalent vaccination represents a recent attempt to improve the effectiveness of lung cancer immunotherapy. This study aimed to investigate whether a gene expression pattern of tumor-associated antigens (TAA) would exist indicating that their use will be most appropriate for the polyvalent vaccination of Caucasian non-small cell lung carcinoma (NSCLC) patients. We examined the concomitant expression of genes belonging to different TAA families for which expression frequencies either have never been detected in NSCLC or vary widely in the literature. Results: 15/23 (65%) and 8/23 (35%) tumor samples were found expressing 6-11 and 2-5 out of the 12 examined TAAs, respectively, at levels >1% of the testis reference sample. The most prevalent TAA patterns observed were those of survivin standard (survivin-std)/survivin-2B expressed by 22/23 (95.5%) tumor samples and of survivin-std/survivin-2B/hTERT expressed by 19/23 (82.5%) tumor samples. The expression levels of the survivin-std gene strongly positively correlated to those of the survivin-2B (p = 0.001) and the hTERT genes (p = 0.031). The number of concomitantly expressed genes was found to be positively correlated to the age of the patients (p = 0.001) and the tumor size (p = 0.048). Methods: Tumor material from 23 patients with NSCLC (12 adenocarcinomas, 8 squamous cell carcinomas, 3 bronchiolo - carcinomas) was examined. mRNA transcripts were detected for 5 genes of the survivin family, 5 MAGE-A genes as well as the genes of human telomerase reverse transcriptase (hTERT) and p53, by the use of quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) or semi-quantitative RT-PCR. Conclusion: This study provides evidence that, in Caucasian patients with NSCLC, highly prevalent expression patterns of TAA genes, predominantly of overexpressed TAAs, do exist. This result implies that the combined use of these TAA could help in designing more effective NSCLC immunotherapeutic protocols.

KW - Human telomerase reverse transcriptase

KW - Immunotherapy

KW - Lung adenocarcinoma

KW - Melanoma-associated antigen

KW - p53

KW - Quantitative real-time PCR

KW - Squamous cell carcinoma

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=45349108941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349108941&partnerID=8YFLogxK

M3 - Article

C2 - 18094614

AN - SCOPUS:45349108941

VL - 7

SP - 345

EP - 352

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -